Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Immunotherapy and targeted therapy-the new roadmap in cancer treatment.

Literature DB >> 31807576

Immunotherapy and targeted therapy-the new roadmap in cancer treatment.

Kamran Shahid¹, Mustafa Khalife¹, Raetasha Dabney¹, Alexandria T Phan¹.

Abstract

Immunotherapy is the new frontier in cancer medicine. This manuscript summarizes historical aspect of immunotherapy, particularly its pathway to drug approval as the main therapeutic modality used in clinical medicine. We will discuss the role of immunotherapy in treating various types of cancers and how the treatment landscape once dominated by chemotherapy is rapidly changing. 2019 Annals of Translational Medicine. All rights reserved.

Entities: Disease

Keywords: Immunotherapy; cancer treatment; check point inhibitors; chimeric antigen receptor T-cells (CAR T-cells)

Year: 2019 PMID： 31807576 PMCID： PMC6861781 DOI： 10.21037/atm.2019.05.58

Source DB: PubMed Journal: Ann Transl Med ISSN： 2305-5839

28 in total

1. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study.

Authors: Ezra E W Cohen; Denis Soulières; Christophe Le Tourneau; José Dinis; Lisa Licitra; Myung-Ju Ahn; Ainara Soria; Jean-Pascal Machiels; Nicolas Mach; Ranee Mehra; Barbara Burtness; Pingye Zhang; Jonathan Cheng; Ramona F Swaby; Kevin J Harrington
Journal: Lancet Date: 2018-11-30 Impact factor: 79.321

Review 2. Treatment of metastatic melanoma: a multidisciplinary approach.

Authors: Paolo Fava; Chiara Astrua; Martina Sanlorenzo; Simone Ribero; Matteo Brizio; Andrea R Filippi; Elena Marra; Franco Picciotto; Dario Sangiolo; Fabrizio Carnevale-Schianca; Massimo Aglietta; Sergio Sandrucci; Umberto Ricardi; Virginia Caliendo; Pietro Quaglino; Maria T Fierro
Journal: G Ital Dermatol Venereol Date: 2017-03-14 Impact factor: 2.011

3. Nivolumab in recurrent/metastatic head and neck cancers.

Authors: Andy Karabajakian; Thibaut Reverdy; Max Gau; Jérôme Fayette
Journal: Future Oncol Date: 2017-11-13 Impact factor: 3.404

4. Nivolumab in the Treatment of Refractory Pediatric Hodgkin Lymphoma.

Authors: Alexandra E Foran; Helen R Nadel; Anna F Lee; Kerry J Savage; Rebecca J Deyell
Journal: J Pediatr Hematol Oncol Date: 2017-07 Impact factor: 1.289

5. ZEB1 suppression sensitizes KRAS mutant cancers to MEK inhibition by an IL17RD-dependent mechanism.

Authors: David H Peng; Samrat T Kundu; Jared J Fradette; Lixia Diao; Pan Tong; Lauren A Byers; Jing Wang; Jaime Rodriguez Canales; Pamela A Villalobos; Barbara Mino; Yanan Yang; Rosalba Minelli; Michael D Peoples; Christopher A Bristow; Timothy P Heffernan; Alessandro Carugo; Ignacio I Wistuba; Don L Gibbons
Journal: Sci Transl Med Date: 2019-03-13 Impact factor: 17.956

Review 6. Immunotherapy of Hodgkin Lymphoma: Mobilizing the Patient's Immune Response.

Authors: Stephen M Ansell
Journal: Cancer J Date: 2018 Sep/Oct Impact factor: 3.360

7. Comparison of immune infiltrates in melanoma and pancreatic cancer highlights VISTA as a potential target in pancreatic cancer.

Authors: Jorge Blando; Anu Sharma; Maria Gisela Higa; Hao Zhao; Luis Vence; Shalini S Yadav; Jiseong Kim; Alejandro M Sepulveda; Michael Sharp; Anirban Maitra; Jennifer Wargo; Michael Tetzlaff; Russell Broaddus; Matthew H G Katz; Gauri R Varadhachary; Michael Overman; Huamin Wang; Cassian Yee; Chantale Bernatchez; Christine Iacobuzio-Donahue; Sreyashi Basu; James P Allison; Padmanee Sharma
Journal: Proc Natl Acad Sci U S A Date: 2019-01-11 Impact factor: 12.779

Review 8. Advances in CD30- and PD-1-targeted therapies for classical Hodgkin lymphoma.

Authors: Yucai Wang; Grzegorz S Nowakowski; Michael L Wang; Stephen M Ansell
Journal: J Hematol Oncol Date: 2018-04-23 Impact factor: 17.388

9. A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naïve patients with advanced melanoma.

Authors: Evan M Hersh; Steven J O'Day; John Powderly; Khuda D Khan; Anna C Pavlick; Lee D Cranmer; Wolfram E Samlowski; Geoffrey M Nichol; Michael J Yellin; Jeffrey S Weber
Journal: Invest New Drugs Date: 2010-01-16 Impact factor: 3.651

10. Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial.

Authors: Philippe Armand; Andreas Engert; Anas Younes; Michelle Fanale; Armando Santoro; Pier Luigi Zinzani; John M Timmerman; Graham P Collins; Radhakrishnan Ramchandren; Jonathon B Cohen; Jan Paul De Boer; John Kuruvilla; Kerry J Savage; Marek Trneny; Margaret A Shipp; Kazunobu Kato; Anne Sumbul; Benedetto Farsaci; Stephen M Ansell
Journal: J Clin Oncol Date: 2018-03-27 Impact factor: 44.544

5 in total

Review 1. Nanotechnology synergized immunoengineering for cancer.

Authors: Deepak S Chauhan; Anupam Dhasmana; Partha Laskar; Rajendra Prasad; Nishant K Jain; Rohit Srivastava; Meena Jaggi; Subhash C Chauhan; Murali M Yallapu
Journal: Eur J Pharm Biopharm Date: 2021-03-24 Impact factor: 5.589

Review 2. Immunotherapy by mesenchymal stromal cell delivery of oncolytic viruses for treating metastatic tumors.

Authors: A-Rum Yoon; Cosette Rivera-Cruz; Jeffrey M Gimble; Chae-Ok Yun; Marxa L Figueiredo
Journal: Mol Ther Oncolytics Date: 2022-03-19 Impact factor: 7.200

3. Safety and Efficacy of an Oncolytic Adenovirus as an Immunotherapy for Canine Cancer Patients.

Authors: Clara Martín-Carrasco; Pablo Delgado-Bonet; Beatriz Davinia Tomeo-Martín; Josep Pastor; Claudia de la Riva; Paula Palau-Concejo; Noemí Del Castillo; Javier García-Castro; Ana Judith Perisé-Barrios
Journal: Vet Sci Date: 2022-06-28

4. Electrospun Silk Fibroin/Polylactic-co-glycolic Acid/Black Phosphorus Nanosheets Nanofibrous Membrane with Photothermal Therapy Potential for Cancer.

Authors: Xia Li; Jiale Zhou; Haiyan Wu; Fangyin Dai; Jiashen Li; Zhi Li
Journal: Molecules Date: 2022-07-18 Impact factor: 4.927

5. The lipid peroxidation derived DNA adduct γ-OHPdG levels in paraneoplastic liver tissues predict postoperative outcomes of hepatoma.

Authors: Yang-Yi Feng; Jen Yu; Yi Hsuan Huang; Yang-Hsiang Lin; Chau-Ting Yeh
Journal: J Cancer Date: 2021-05-13 Impact factor: 4.207

5 in total